Senseonics HoldingsSENS
SENS
About: Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.
Employees: 117
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
164% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 11
60% more call options, than puts
Call options by funds: $758K | Put options by funds: $475K
36% more capital invested
Capital invested by funds: $41.8M [Q4 2024] → $56.9M (+$15.1M) [Q1 2025]
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
14% more funds holding
Funds holding: 124 [Q4 2024] → 141 (+17) [Q1 2025]
0.11% less ownership
Funds ownership: 13.42% [Q4 2024] → 13.31% (-0.11%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.40
182%
upside
Avg. target
$1.40
182%
upside
High target
$1.40
182%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Sean Lee | 182%upside $1.40 | Buy Maintained | 8 Jul 2025 |
Financial journalist opinion
Neutral
Zacks Investment Research
3 weeks ago
Here's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 Weeks
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Neutral
GlobeNewsWire
1 month ago
Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes
GERMANTOWN, Md., June 04, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it will host an in-person and virtual analyst event in conjunction with the American Diabetes Association 85th Scientific Sessions (ADA 2025), on Saturday, June 21, 2025 at 8:00am CT at the Marriot Marquis Chicago. To register, click here.
Neutral
GlobeNewsWire
1 month ago
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of a total of 115,000,000 shares of its common stock, which included the exercise in full by the underwriters of their option to purchase up to an additional 15,000,000 shares of common stock, at a public offering price of $0.50 per share.
Positive
Seeking Alpha
1 month ago
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market dominated by short-term CGMs from DexCom, Abbott Laboratories, and Medtronic. The next 12 months will be crucial for Senseonics as they prove their technology and decide if they continue their commercial partnership with Ascensia, change partners to go solo.
Neutral
GlobeNewsWire
1 month ago
Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 100,000,000 shares of common stock at a price to the public of $0.50 per share of common stock. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $50,000,000. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 19, 2025, subject to satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
1 month ago
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. In connection with the proposed offering, Senseonics also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of shares of common stock offered in the public offering. All of the shares of common stock to be sold in the proposed offering will be offered by Senseonics.
Neutral
Zacks Investment Research
2 months ago
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Neutral
Seeking Alpha
2 months ago
Senseonics Holdings, Inc. (SENS) Q1 2025 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Operator Good day, everyone, and welcome to the Senseonics First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode.
Neutral
GlobeNewsWire
2 months ago
Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 8, 2025.
Neutral
GlobeNewsWire
2 months ago
Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)
twiist™ expands compatibility offerings to become the first AID system compatible with Senseonics Eversense® 365 one-year CGM system
Charts implemented using Lightweight Charts™